• Explore /
  • Poster
  • / Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

Preliminary immunogenicity, safety, and efficacy of JNJ-64041757 (JNJ-757) in non-small cell lung cancer (NSCLC): Results from two phase 1 studies.

Abstract Poster

Authors

null

Julie R. Brahmer

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD

Julie R. Brahmer , Melissa Lynne Johnson , Manuel Cobo Dols , Santiago Viteri Ramirez , Juan Coves , Ammar Sukari , Mark M. Awad , Ravi Salgia , Vassiliki Papadimitrakopoulou , Arun Rajan , Alicia Jones Allred , Mark Wade , Gary Mason , Enrique Zudaire , Roland Elmar Knoblauch , Nicole L. Stone , Matthew V. Lorenzi , Raffit Hassan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT02592967, NCT03371381

Citation

J Clin Oncol 37, 2019 (suppl; abstr 9093)

DOI

10.1200/JCO.2019.37.15_suppl.9093

Abstract #

9093

Poster Bd #

416

Abstract Disclosures

Similar Posters

First Author: Panpan Zhang

First Author: Kai He

First Author: Naoki Furuya

First Author: Thorsten Oliver Goetze